EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Seeing in the Future – a Perspective on Combining Light with Chemical Biology Approaches to Treat Retinal Pathologies

Alexandre Specht iD, Maxime Klimezak, Sidney Cambridge iD

ChemMedChem · 2025

DOI: 10.1002/cmdc.202400827 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ChemMedChem, 2025. Verfasst von Alexandre Specht und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire de Chémo-Biologie Synthétique et Thérapeutique (CBST), Équipe Nanoparticules Intelligentes, Université de Strasbourg, CNRS, CBST UMR 7199…. Hauptthemen laut MEDLINE: Retinal Diseases, Light, Retina, Photosensitizing Agents. Die Arbeit nennt 86 Literaturangaben. Gefördert von: Université de Strasbourg, CNRS, Agence Nationale de la Recherche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

New concepts to treat eye diseases have emerged that elegantly combine unnatural light exposure with chemical biology approaches to achieve superior cellular specificity and, as a result, improvement of visual function. Historically, light exposure without further molecular eye treatment has offered limited success including photocoagulation to halt pathological blood vessel growth or low light exposure to stimulate retinal cell viability. To add cellular specificity to such treatments, researchers have introduced various biological or chemical light‐sensing molecules and combined those with light exposure. (Pre‐)clinical trials describe the use of optogenetics and channelrhodpsins, i. e. light‐sensitive ion channels, in patient vision restoration. In the chemical arena, pharmacological agents, rendered light‐sensitive by reversible modification with photosensitive protecting compounds (“caging”), have been applied to eyes of living mice to photo‐release specific cellular activities. Among these were successful proof‐of‐principle experiments that were conducted to establish photo‐sensitive gene therapies in the eye. For light‐mediated treatment in combination with chemical biology, we wish to describe here the current frontiers of research in vision restoration with an eye on differences between biological and chemical light‐sensing molecules, patient requirements, and future outlooks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retinal DiseasesLightRetinaPhotosensitizing AgentsHumansAnimalsOptogenetics

Stichwörter der Autor:innen

Caged compundsLight triggersOcular pathologiesOptogeneticsPDT

Substanzen

Photosensitizing Agents

Autor:innen und Institutionen

  • Laboratoire de Chémo-Biologie Synthétique et Thérapeutique (CBST), Équipe Nanoparticules Intelligentes, Université de Strasbourg, CNRS, CBST UMR 7199, F-67401, Illkirch Cedex, France.
  • Department of Physiological Chemistry, University Medical Center of Johannes Gutenberg University Mainz, 55128, Mainz, Germany.

ORCID-Profile: Alexandre Specht, Sidney Cambridge

Förderung

  • Université de Strasbourg
  • CNRS
  • Agence Nationale de la Recherche
  • DFG
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Specht, A., Klimezak, M., & Cambridge, S. (2025). Seeing in the Future – a Perspective on Combining Light with Chemical Biology Approaches to Treat Retinal Pathologies. ChemMedChem. https://doi.org/10.1002/cmdc.202400827

Vancouver

Specht A, Klimezak M, Cambridge S. Seeing in the Future – a Perspective on Combining Light with Chemical Biology Approaches to Treat Retinal Pathologies. ChemMedChem. 2025. doi:10.1002/cmdc.202400827

BibTeX
@article{Specht2025,
  author = {Specht, Alexandre and Klimezak, Maxime and Cambridge, Sidney},
  title = {Seeing in the Future – a Perspective on Combining Light with Chemical Biology Approaches to Treat Retinal Pathologies},
  journal = {ChemMedChem},
  year = {2025},
  doi = {10.1002/cmdc.202400827}
}
Kostenlos starten →